Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects

Preclinical characterization of velpatasvir (VEL; GS-5816), an inhibitor of the hepatitis C virus (HCV) NS5A protein, demonstrated that it has favorable in vitro and in vivo properties, including potent antiviral activity against hepatitis C virus genotype 1 to 6 replicons, good metabolic stability,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Antimicrob Agents Chemother
Autori principali: Mogalian, Erik, German, Polina, Kearney, Brian P., Yang, Cheng Yong, Brainard, Diana, Link, John, McNally, John, Han, LingLing, Ling, John, Mathias, Anita
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2017
Soggetti:
Antiviral Agents
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5404583/
https://ncbi.nlm.nih.gov/pubmed/28193657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02084-16
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi